BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1766671)

  • 1. Mutations in the p53 gene in myelodysplastic syndromes.
    Jonveaux P; Fenaux P; Quiquandon I; Pignon JM; Laï JL; Loucheux-Lefebvre MH; Goossens M; Bauters F; Berger R
    Oncogene; 1991 Dec; 6(12):2243-7. PubMed ID: 1766671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of p53 gene mutations in primary neuroblastomas.
    Vogan K; Bernstein M; Leclerc JM; Brisson L; Brossard J; Brodeur GM; Pelletier J; Gros P
    Cancer Res; 1993 Nov; 53(21):5269-73. PubMed ID: 8221661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutations in ovarian cancer: a late event?
    Mazars R; Pujol P; Maudelonde T; Jeanteur P; Theillet C
    Oncogene; 1991 Sep; 6(9):1685-90. PubMed ID: 1923532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma.
    Kim JW; Cho YH; Kwon DJ; Kim TE; Park TC; Lee JM; Namkoong SE
    Gynecol Oncol; 1995 May; 57(2):199-204. PubMed ID: 7729734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular study on minute alterations of the p53 and the N-ras genes in hematologic malignancies].
    Kurosawa M
    Hokkaido Igaku Zasshi; 1994 May; 69(3):543-54. PubMed ID: 7927179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
    Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
    Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma.
    Adesina AM; Nalbantoglu J; Cavenee WK
    Cancer Res; 1994 Nov; 54(21):5649-51. PubMed ID: 7923211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products.
    Mashiyama S; Murakami Y; Yoshimoto T; Sekiya T; Hayashi K
    Oncogene; 1991 Aug; 6(8):1313-8. PubMed ID: 1886708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer.
    Okamoto A; Sameshima Y; Yokoyama S; Terashima Y; Sugimura T; Terada M; Yokota J
    Cancer Res; 1991 Oct; 51(19):5171-6. PubMed ID: 1680546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis.
    Lepelley P; Preudhomme C; Vanrumbeke M; Quesnel B; Cosson A; Fenaux P
    Leukemia; 1994 Aug; 8(8):1342-9. PubMed ID: 8057671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism.
    Yoshimoto K; Iwahana H; Fukuda A; Sano T; Saito S; Itakura M
    Cancer Res; 1992 Sep; 52(18):5061-4. PubMed ID: 1516062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus.
    Okamoto A; Sameshima Y; Yamada Y; Teshima S; Terashima Y; Terada M; Yokota J
    Cancer Res; 1991 Oct; 51(20):5632-5. PubMed ID: 1913680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis.
    Murakami Y; Hayashi K; Sekiya T
    Cancer Res; 1991 Jul; 51(13):3356-61. PubMed ID: 2054775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonality studies and N-ras and p53 mutation analysis of hematopoietic cells in Fanconi anemia.
    Venkatraj VS; Gaidano G; Auerbach AD
    Leukemia; 1994 Aug; 8(8):1354-8. PubMed ID: 8057673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the p53 gene occur in diverse human tumour types.
    Nigro JM; Baker SJ; Preisinger AC; Jessup JM; Hostetter R; Cleary K; Bigner SH; Davidson N; Baylin S; Devilee P
    Nature; 1989 Dec; 342(6250):705-8. PubMed ID: 2531845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of the p53 gene are not detectable in human testicular tumors.
    Fleischhacker M; Strohmeyer T; Imai Y; Slamon DJ; Koeffler HP
    Mod Pathol; 1994 May; 7(4):435-9. PubMed ID: 8066072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53 mutation in advanced stage of primary myelodysplastic syndrome.
    Tang JL; Tien HF; Lin MT; Chen PJ; Chen YC
    Anticancer Res; 1998; 18(5B):3757-61. PubMed ID: 9854490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases.
    Yamada Y; Yoshida T; Hayashi K; Sekiya T; Yokota J; Hirohashi S; Nakatani K; Nakano H; Sugimura T; Terada M
    Cancer Res; 1991 Nov; 51(21):5800-5. PubMed ID: 1933850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours.
    Prosser J; Thompson AM; Cranston G; Evans HJ
    Oncogene; 1990 Oct; 5(10):1573-9. PubMed ID: 2250913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas.
    Cote RJ; Jhanwar SC; Novick S; Pellicer A
    Cancer Res; 1991 Oct; 51(19):5410-6. PubMed ID: 1913660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.